title: Proteinuria: abate or applaud abatacept in proteinuric kidney disease?
abstract: T-lymphocyte activation antigen CD80 is a B-cell costimulator and podocyte injury marker originally described in lupus nephritis; CD80 blockade with abatacept disappointed in a lupus nephritis trial. A study now suggests abatacept efficacy in focal and segmental glomerulosclerosis. Small patient numbers and concurrent treatment regimens call for more definitive studies regarding this therapeutic strategy.
authors.affiliation: Department of Medicine, Rush University Medical Center, 1735 West Harrison Street, Cohn Building, Suite 724, Chicago, IL 60612, USA.
authors.forename: Jochen
authors.initials: J
authors.lastname: Reiser
authors.affiliation: Department of Medicine, Johns Hopkins University School of Medicine, Johns Hopkins Hospital, 600 Wolfe Street, Brady 502, Baltimore, MD 21287, USA.
authors.forename: Nada
authors.initials: N
authors.lastname: Alachkar
mesh_terms: D000069594:Abatacept; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects / Q000276:immunology*; D018796:Immunoconjugates / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D011507:Proteinuria / Q000188:drug therapy / Q000276:immunology / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D018796:Immunoconjugates; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D000069594:Abatacept